舒肝解郁胶囊治疗卒中后抑郁的临床研究

目的:观察舒肝解郁胶囊治疗卒中后抑郁的疗效和副反应。方法:将120例卒中后抑郁病人随机分为治疗组和对照组,两组病人均给予脑梗死常规治疗,治疗组服用舒肝解郁胶囊,对照组服用氟西汀胶囊,疗程8周。分别于治疗前,治疗第2,4,8周末采用汉密尔顿抑郁量表(HAMD)、副反应量表(TESS)评定疗效和不良反应。结果:至研究终点,两组HAMD评分均显著低于治疗前(P<0.05),但两组间比较差异无统计学意义(P>0.05);治疗组和对照组有效率分别为86.67%,83.33%,差异无统计学意义(P>0.05);治疗组的TESS评分显著低于对照组(P<0.05)。结论:舒肝解郁胶囊治疗卒中后抑郁与氟西汀相当,疗效确切,不良反应明显少于后者。

Efficacy of Shuganjieyu capsule for the treatment of Post-stroke depression

Objective: To observe the clinical evaluation and side effects of shuganjieyu capsule for treatment of post-stroke depression.Methods: A total of 120 patients with post-stroke depression were randomly divided into the treatment group and the control group. The treatment group was treated with Shuganjieyu capsule, and the control group was treated with Fluoxetine for 8 weeks, Two groups were almost equal on the basis of routine treatment. The therapeutic efifcacy and adverse reactions were evaluated at the beginning and by the end of 2-,4-,8-week after treatment by Hamilton Depression Scale (HAMD) and Treatment Emergent Symptoms Scale (TESS). Results: By the end of study, the scores of HAMD were significantly lower than those at the beginning (P<0.05), and no statistically signiifcant difference was found between two groups (P>0.05); the effective ratios of the treatment group and the control group were 86.67%and 83.33% respectively with no statistically signiifcant difference between two groups too (P>0.05); The TESS was conspicuously fewer in the test group than that in the control group (P<0.05).Conclusion: Shuganjieyu capsule presents the similar effect as Fluoxetine in treating post-stroke depression patients with less side effects.